Human Cell Design models are designed for fast and reliable studies with reproducible results. As we aim to empower research teams with the best technology to generate better human data, we are proud to discover that data involving Endoc-βH® models has recently been published.


Endoc-βH1® represents a relevant model for Type I diabetes


The research team of Dr. Decio Eizirik from Université Libre de Bruxelles (ULB), and Indiana Biosciences Research Institute established the importance of tyrosine kinase inhibitors for human beta cell protection in type 1 diabetes. Dr. Eizirik team used Endoc-βH1® human beta cells to evaluate effect of tyrosine kinase inhibitors on IFNα signaling, beta-cell function and susceptibility to viral infection.

Dr. Eizirik team succeeded in demonstrating that two TYK2 inhibitors significantly inhibit the IFNα signaling pathway in human beta cells, decreasing its pro-inflammatory and pro-apoptotic effects without sensitizing the cells to viral infection. These preclinical findings could pave the way for future clinical trials with TYK2 inhibitors for the prevention and treatment of type 1 diabetes.

The full publication is available for free here if you wish to learn more about Dr. Eizirik’s work.


Endoc-βH1®, immortalized insulin producing human beta cells dedicated to assay development and Type I and II Diabetes drug discovery


At Human Cell Design, we support innovative research by always providing you with the best translational tools to achieve your goals and to generate high-ranking international publications.


Comments are closed.